Literature DB >> 26265385

Future therapy for hepatitis B virus infection.

Masahito Minami1.   

Abstract

We can now control hepatitis B virus infection by continuously administering nucleoside and nucleotide analogues such as entecavir and tenofovir. These drugs are generally safe and sufficiently effective, but future drugs are needed that can show off-treatment efficacy--in other words, eradication of latent hepatitis B virus DNA (covalently closed circular DNA) in the hepatocytes. This article is an overview of new drugs under development and some novel strategies to inhibit hepatitis B virus proliferation.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26265385     DOI： 10.1007/s12328-015-0590-y

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN： 1865-7265


  30 in total

Review 1.  Hepatitis B virus infection--natural history and clinical consequences.

Authors:  Don Ganem; Alfred M Prince
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

Review 2.  EASL Clinical Practice Guidelines: management of chronic hepatitis B.

Authors: 
Journal:  J Hepatol       Date:  2008-10-29       Impact factor: 25.083

3.  Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.

Authors:  Christopher A Benetatos; Yasuhiro Mitsuuchi; Jennifer M Burns; Eric M Neiman; Stephen M Condon; Guangyao Yu; Martin E Seipel; Gurpreet S Kapoor; Matthew G Laporte; Susan R Rippin; Yijun Deng; Mukta S Hendi; Pavan K Tirunahari; Yu-Hua Lee; Thomas Haimowitz; Matthew D Alexander; Martin A Graham; David Weng; Yigong Shi; Mark A McKinlay; Srinivas K Chunduru
Journal:  Mol Cancer Ther       Date:  2014-02-21       Impact factor: 6.261

4.  Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation.

Authors:  Miguel-Angel Perales; Jenna D Goldberg; Jianda Yuan; Guenther Koehne; Lauren Lechner; Esperanza B Papadopoulos; James W Young; Ann A Jakubowski; Bushra Zaidi; Humilidad Gallardo; Cailian Liu; Teresa Rasalan; Jedd D Wolchok; Therese Croughs; Michel Morre; Sean M Devlin; Marcel R M van den Brink
Journal:  Blood       Date:  2012-09-25       Impact factor: 22.113

5.  Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.

Authors:  A B van Nunen; B E Hansen; D J Suh; H F Löhr; L Chemello; H Fontaine; J Heathcote; B C Song; H L A Janssen; R A de Man; S W Schalm
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

Review 6.  Harnessing the biology of IL-7 for therapeutic application.

Authors:  Crystal L Mackall; Terry J Fry; Ronald E Gress
Journal:  Nat Rev Immunol       Date:  2011-05       Impact factor: 53.106

7.  A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.

Authors:  Guang-Bi Yao; Zhen-Yu Cui; Bao-En Wang; Ji-Lu Yao; Min-De Zeng
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2004-05

8.  Side effects of long-term oral antiviral therapy for hepatitis B.

Authors:  Robert J Fontana
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

9.  Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA.

Authors:  Jung Im Seok; Dong Kuck Lee; Chang Hyeong Lee; Min Su Park; Sun Young Kim; Hyang-Sook Kim; Hee-Young Jo; Chang Hun Lee; Dae-Seong Kim
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

Review 10.  NTCP and beyond: opening the door to unveil hepatitis B virus entry.

Authors:  Koichi Watashi; Stephan Urban; Wenhui Li; Takaji Wakita
Journal:  Int J Mol Sci       Date:  2014-02-19       Impact factor: 5.923
View more
  1 in total

Review 1.  Research progress of therapeutic vaccines for treating chronic hepatitis B.

Authors:  Jianqiang Li; Mengru Bao; Jun Ge; Sulin Ren; Tong Zhou; Fengchun Qi; Xiuying Pu; Jia Dou
Journal:  Hum Vaccin Immunother       Date:  2017-01-24       Impact factor: 3.452
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.